Our business model includes partnering and potentially direct sales for commercialization and distribution. Potential licensors and development partners include pharmaceutical, consumer packaged goods companies and others, who would commercialize IBO technologies in exchange for milestone, and royalty payments.
Stage not disclosed · ActiveModality: small molecule (electrophilically enhanced polyphenols)
Aliases Linebacker-1, Linebacker-2
Target PIM kinase
Partnerships ProPhase Laboratories: Linebacker-1 and Linebacker-2 licensed for development and commercialization worldwide; future milestones and royalties to Impact BioMedical.
Indications
Oncology (solid tumors: colon, lung, prostate, breast)(Stage not disclosed)
Inflammatory disorders and neurology(Stage not disclosed)
Status note Platform of modified myricetin compounds that down-regulate PIM kinase. No clinical trials stated in excerpts.
Laetose
Stage not disclosed · ActiveModality: formulation (sugar alternative)
Target TNF-alpha
Indications
Inflammatory or metabolic diseases (e.g., diabetes)(Stage not disclosed)
Status note Patented formulation that lowers caloric intake and glycemic index and inhibits TNF-alpha; no clinical trials stated in excerpts.
Equivir
Stage not disclosed · ActiveModality: polyphenol blend
Aliases Equivir G
Partnerships ProPhase Laboratories: licensed for development and commercialization worldwide. 2022 Equivir License: 5.5% royalty on net sales.
Indications
Viral infections (health supplement or medication)(Stage not disclosed)
Status note Novel blend of GRAS-eligible polyphenols (myricetin, hesperetin, piperine) with demonstrated antiviral effects; no clinical trials stated in excerpts.
Functional Fragrance Formulation
Stage not disclosed · ActiveModality: functional fragrance formulation
Aliases 3F
Target n/a
Partnerships Chemia: joint licensing effort; profits split between Global BioLife and Chemia under 20-year Royalty Agreement.
Status note Suite of functional fragrances (terpenes) as antimicrobial or additive for repellents, detergents, lotions, etc.; commercialization/licensing in progress, not a clinical asset.
Per-asset detail extracted from the 10-Q filed 2026-08-07. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.
No lead program on file for this company.
No active ClinicalTrials.gov trials matched to this company as sponsor or collaborator.
Specialist fund holders
Tracked specialist funds: ADAR1 Capital Management, Aisling Capital, Ally Bridge Group, Avoro Capital Advisors, BVF Partners, Baker Bros. Advisors, Boxer Capital, Braidwell LP, Casdin Capital, Cormorant Asset Management, DAFNA Capital, Deerfield Management, EcoR1 Capital, Frazier Life Sciences, Great Point Partners, Ikarian Capital, Logos Global Management, OrbiMed Advisors, Perceptive Advisors, RA Capital Management, RTW Investments, Sphera Biotech, Stonepine Capital, Tang Capital Partners, Vivo Capital.
None of the tracked specialist funds reported a position in the latest 13F snapshot.
Latest news
Loading headlines…
Headlines from the Fully Diluted live wire: IR newsrooms, newswires, SEC filings, and halt notices, refreshed every 15 minutes.
Get the weekly biotech catalyst rundown. Cash runways, financings, and trial readouts for all 721 stocks.